Equity in Biomedicine Seminar: Need for increased genetic diversity in cell line models and CRISPR experimental tools

The Broad Institute's Lindy Barrett, Ralda Nehme, Sean Misek and MIT's Jesse Boehm present on the ways that genetic ancestry can limit scientific understanding and impact equity in downstream translational benefits. Lindy Barrett and Ralda Nehme discuss why increasing genetic diversity of pluripotent stem cell models is critical for ensuring equitable and broadly useful scientific insights and translational benefits. Sean Misek and Jesse Boehm discuss their work showing how genetic ancestry-based CRISPR guide bias can lead to false negatives in cell-based screens.

Speakers

Sean Misek
Cancer Program
Broad Institute

Jesse Boehm
Break Through Cancer

Ralda Nehme
Stanley Center for Psychiatric Research

Stem Cell Program
Broad Institute

Lindy Barrett
Stanley Center for Psychiatric Research
Broad Institute

Visiting Scholar
Harvard University

Moderator

Anne Carpenter
Broad Institute

About the Equity in Biomedicine Seminar Series (EBM)
This video is part of the Equity in Biomedicine Seminar Series (EBM), an institute-wide interactive meeting that focuses on critical issues related to equity and representation in biomedical research, especially as it applies to genomics research and precision medicine. Speakers dive into the equal or unequal social implications of their work: Who is affected? How are they affected? Why? The overall goal of this series is to foster discussions about equity and inspire Broad scientists and trainees to reflect on the social impact of their own research.

The EBM series is sponsored by the IDEA Office; each event in the series is presented by one or more Broad scientific groups in collaboration with Shades@Broad and the organizing committee. For more information about the EBM series or to nominate a future seminar speaker, contact Mireille Kamariza.